Growth & profitability
- Revenue has grown 319.7% per year over the past 5 years.
- Operating margin has expanded, at 48.2% in the latest year.
Financial health
- Operating income covered interest expense 54× in the latest year.
CRMD Financials Cormedix Inc.
15 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
RevenueNet income
GrossOperatingNet
Free cash flow
CashTotal debt
OperatingInvestingFinancing
Key annual figures
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $312M | $163M | 88.5% | 48.2% | $173M | — | $145M |
| 2024 | $43M | -$18M | 92.7% | -51.4% | -$51M | — | $41M |
| 2023 | — | -$46M | — | — | -$39M | — | $44M |
| 2022 | $65408 | -$30M | 94.3% | -46819.9% | -$25M | — | $43M |
| 2021 | $190936 | -$28M | 22.0% | -15417.5% | -$23M | — | $53M |
| 2020 | $239231 | -$22M | 14.4% | -11378.4% | -$22M | — | $42M |
| 2019 | $283266 | -$16M | -31.8% | -7416.3% | -$15M | — | $16M |
| 2018 | $429797 | -$27M | 7.7% | -6250.4% | -$24M | — | $18M |
| 2017 | $329327 | -$33M | 65.1% | -9997.4% | -$29M | — | $10M |
| 2016 | $224105 | -$25M | -63.6% | -11048.8% | -$22M | — | $8M |
| 2015 | $210130 | -$18M | -51.7% | -7925.6% | -$13M | — | $12M |
| 2014 | $189274 | -$20M | -135.5% | -4703.3% | -$6M | — | $4M |
| 2014 | $14204 | -$72M | -1889.8% | -308570.0% | -$29M | — | $9M |
| 2013 | $2001 | -$9M | -9975.2% | -245646.9% | -$4M | — | $2M |
| 2013 | — | $52M | — | — | -$27M | — | $483052 |
RevenueNet income
GrossOperatingNet
Free cash flow
CashTotal debt
OperatingInvestingFinancing
Key quarterly figures
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | $127M | $39M | 82.5% | 50.0% | $42M | — | $178M |
| Dec '25 | — | $14M | — | — | $93M | — | $145M |
| Sep '25 | — | $109M | — | — | $30M | — | $48M |
| Jun '25 | — | $20M | — | — | $30M | — | $159M |
| Mar '25 | $39M | $21M | 95.9% | 51.5% | $20M | — | $66M |
| Dec '24 | — | $13M | — | — | -$6M | — | $41M |
| Sep '24 | — | -$3M | — | — | -$14M | — | $35M |
| Jun '24 | — | -$14M | — | — | -$14M | — | $29M |
| Mar '24 | — | -$14M | — | — | -$17M | — | $35M |
| Dec '23 | — | -$15M | — | — | -$11M | — | $44M |
| Sep '23 | — | -$10M | — | — | -$9M | — | $53M |
| Jun '23 | — | -$11M | — | — | -$9M | — | $20M |
| Mar '23 | — | -$11M | — | — | -$10M | — | $25M |
| Dec '22 | — | -$8M | — | — | -$6M | — | $43M |
| Sep '22 | — | -$7M | — | — | -$6M | — | $43M |
| Jun '22 | — | -$8M | — | — | -$5M | — | $49M |
| Mar '22 | — | -$7M | — | — | -$7M | — | $45M |
| Dec '21 | — | -$8M | — | — | -$6M | — | $53M |
| Sep '21 | — | -$9M | — | — | -$6M | — | $66M |
| Jun '21 | — | -$5M | — | — | -$3M | — | $73M |
Valuation over time
How the market has priced CRMD against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
- The price-to-earnings ratio has fallen from 5.6× (Dec '25) to 3.7× (Jun '26).
- The price-to-sales ratio has fallen from 4947.6× (Mar '23) to 1.9× (Jun '26).
P/E
P/S
Frequently asked questions
Is CRMD growing its revenue and profit?
Over the past 5 years, Cormedix Inc.'s revenue has grown 319.7% per year. These are computed facts, not advice.
How much debt does CRMD have?
As of FY2025, Cormedix Inc. reported — of total debt against $145M of cash; operating income covered interest expense 54×.
What is CRMD's profit margin?
In FY2025, gross margin was 88.5%, operating margin 48.2%, and net margin 52.3%.
What is CRMD's P/E ratio?
As of Jun '26, Cormedix Inc. traded at a price-to-earnings ratio of about 3.7× (market cap ÷ latest annual net income). The valuation charts above show how its P/E, P/S have moved with the share price. These are computed facts, not advice.
Where does this data come from?
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.